Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftriaxone–tazobactam (6:1) vs (3:1) in acute bacterial lower respiratory and urinary tract infections
CTR20150076Phase 3Active
- Sponsor
- Xiangbei Welman Pharmaceuticals
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ceftriaxone + tazobactam in Acute bacterial lower respiratory tract infection (ABLRTI), Acute Urinary Tract Infection (UTI), sponsored by Xiangbei Welman Pharmaceuticals. Started Apr 2015; status: active.
02
Drugs
ceftriaxone + tazobactam
03
Conditions
Acute bacterial lower respiratory tract infection (ABLRTI)Acute Urinary Tract Infection (UTI)
Beyond the preview
Go deeper on CTR20150076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150076.